The introduction of Intraocular Anti-VEGFs agents have significantly improved the management of a wide variety of neovscular ocular diseases including retinopathy of prematurity (ROP). In our hands, monotherapy treatment with intravitreal bevacizumab (IVB) is a favourable treatment modality in management of threshold ROP. In eyes with iris rubeosis, rigid pupils and vitreous haze where it is difficult to visualize the fundus and perform laser retinal photocaoagulation, IVB leads to dramatic regression of iris rubeosis and retinal neovascualrization and improves visualization, of the fundus. Unlike with laser therapy, retinal vessels continue to grow towards the periphery after IVB treatment. IVB is an inexpensive drug that can be rapidly administered at the bedside by trained ophthalmologist under topical anaesthesia, in contrast to conventional laser photocoagulation that could be more difficult to administer in ROP eyes. Moreover, because bevacizumab is a large molecule and the vitreous gel in the neonate being more viscous, systemic absorption is likely to be limited.